UK markets open in 1 hour 8 minutes
NIKKEI 225
39,045.53 +428.43 (+1.11%) HANG SENG
18,875.37 -320.23 (-1.67%) CRUDE OIL
76.93 -0.64 (-0.83%) GOLD FUTURES
2,368.80 -24.10 (-1.01%) DOW
39,671.04 -201.95 (-0.51%) Bitcoin GBP
54,511.85 -365.32 (-0.67%)
Oxford BioMedica plc (OXB.L)
LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
At close: 04:35PM BST
| Previous close | 331.50 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 370,492 |
| Market cap | 328.5M |
| Beta (5Y monthly) | 0.94 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.63 |
| Earnings date | 29 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 414.67 |
Simply Wall St.Oxford Biomedica Full Year 2023 Earnings: Misses Expectations
Oxford Biomedica ( LON:OXB ) Full Year 2023 Results Key Financial Results Revenue: UK£89.5m (down 36% from FY 2022...
Simply Wall St.Oxford Biomedica Insiders Placed Bullish Bets Worth UK£415.3k
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
Globe NewswireUpdate to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results
Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results Three-year revenue CAGR increased to more than 35%, up from prior guidance of more than 30%Projected FY2024 revenue range of £126 million to £134 million, reflecting the successful integration of ABL Europe and anticipated growth from new and existing client programmesFY2023 revenues and EBITDA expected to be in line with guidance provided at the Interim ResultsFY2023 Preliminary Results to be reported on
© 2024 Yahoo. All rights reserved.